Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Raynaud's Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Raynaud's Disease. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-000397-23 Sponsor Protocol Number: SLx-2101-07-04 Start Date*: 2007-05-29
    Sponsor Name:Surface Logix, Inc.
    Full Title: A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days ...
    Medical condition: Raynaud's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037917 Raynauds LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001899-38 Sponsor Protocol Number: BAY63-2521/16787 Start Date*: 2013-07-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after o...
    Medical condition: Patients with 1° and 2° Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000309-10 Sponsor Protocol Number: CHUBX2017/45 Start Date*: 2021-10-04
    Sponsor Name:CHU de Bordeaux
    Full Title: Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Ray...
    Medical condition: Raynaud phenomenon
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013468-37 Sponsor Protocol Number: Protocol code BA7 Start Date*: 2010-09-29
    Sponsor Name:Royal National Hospital for Rheumatic Disease
    Full Title: A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon.
    Medical condition: Primary Raynaud's Phenomenon and Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042953 Systemic Sclerosis LLT
    12.0 10037917 Raynaud's phenomenon LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019009-40 Sponsor Protocol Number: A7331010 Start Date*: 2010-07-08
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci...
    Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037912 Raynaud's phenomenon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-024005-13 Sponsor Protocol Number: 3098009 Start Date*: 2011-03-11
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste...
    Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003203-35 Sponsor Protocol Number: VP-C21-004 Start Date*: 2019-12-13
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ...
    Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002081-13 Sponsor Protocol Number: GS-2001 Start Date*: 2020-09-08
    Sponsor Name:Gesynta Pharma AB
    Full Title: A Phase II, randomised, multi-centre placebo-controlled, double-blind study to investigate the safety of GS-248, and efficacy on Raynaud’s phenomenon (RP) and peripheral vascular blood flow in pati...
    Medical condition: Raynaud's phenomenon (RP) in patients with Systemic sclerosis (SSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037917 Raynauds LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-018194-31 Sponsor Protocol Number: PIL001 Start Date*: 2010-11-03
    Sponsor Name:Pharmarama International Limited
    Full Title: Topical Amlodipine in Raynaud's Phenomenon
    Medical condition: The medical conditions under investigation in this trial are as follows: 1] Primary Raynaud's Phenomenon 2] Systemic Sclerosis (SSc) - otherwise known an Seconday Raynaud's Phenomenon. Raynaud's ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000295-41 Sponsor Protocol Number: Ro-002/05 Start Date*: 2006-05-29
    Sponsor Name:Universität zu Köln
    Full Title: Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynau...
    Medical condition: Raynaud´s disease (RD) is defined as episodic, painful, cold- or emotional stress-triggered vasospasms of the digital arteries and precapillary arterioles for up to 30 minutes with or without under...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004596-12 Sponsor Protocol Number: 110905 Start Date*: 2014-01-22
    Sponsor Name:Azienda ospedaliera universitaria Ospedali Riuniti
    Full Title: HOME INFUSION THERAPY WITH ILOPROST USING A PORTABLE SYRINGE PUMP FOR THE TREATMENT OF PERIPHERAL ULCERS AND RAYNAUD'S PHENOMENON IN SYSTEMIC SCLEROSIS.
    Medical condition: Raynaud's phenomenon and acral ulcers in systemic sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019977-14 Sponsor Protocol Number: CILOS-RAY2010 Start Date*: 2010-11-04
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis
    Medical condition: Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002984-32 Sponsor Protocol Number: FER-COM-16-004 Start Date*: 2017-02-16
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Treatment of the Reynaud's Disease associated with ischemic ulcers in patients affected by sistemic sclerosis
    Medical condition: SISTEMIC SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005723-20 Sponsor Protocol Number: RC31/20/0445 Start Date*: 2022-02-10
    Sponsor Name:CHU de Toulouse
    Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease
    Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001719-65 Sponsor Protocol Number: CALC-SSc Start Date*: 2018-12-10
    Sponsor Name:University Medial Center Groningen
    Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study
    Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001617-27 Sponsor Protocol Number: IVA_01_337_HSSC_15_001 Start Date*: 2015-09-18
    Sponsor Name:Inventiva SAS
    Full Title: A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis
    Medical condition: Systemic sclerosis (scleroderma) (SSc) is a chronic connective tissue disorder of unknown aetiology characterized by widespread microvascular damage and excessive deposition of collagen in the skin...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10012941 Diffuse scleroderma LLT
    18.0 100000004859 10074034 Generalised scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed) DE (Completed) NL (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001101-40 Sponsor Protocol Number: 13/0417 Start Date*: 2015-02-24
    Sponsor Name:University College London (UCL)
    Full Title: Sclero XIII: A phase II ,double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic...
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10010759 Connective tissue disorder NOS LLT
    17.1 100000004859 10018124 Generalized scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001817-33 Sponsor Protocol Number: GLPG1690-CL-204 Start Date*: 2019-01-14
    Sponsor Name:Galapagos NV
    Full Title: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic...
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005230-20 Sponsor Protocol Number: NOT AVAILABLE Start Date*: 2006-07-14
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: EX VIVO EFFECT OF AMINAFTONE (CAPILLAREMA) ON THE ENDOTELIAL FUNCTION IN SYSTEMIC SCLEROSIS. Effetto ex vivo dell’aminaftone (Capillarema) sulla funzione endoteliale nella Sclerosi Sistemica
    Medical condition: Variazione della gravita' del fenomeno di Raynaud misurata mediante diario dei sintomi e scala analogica visiva VAS ﾖ Visual Analogic Scale (6). Variazione dello stato globale di malattia valutat...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004937-19 Sponsor Protocol Number: CMHV370A12201 Start Date*: 2021-09-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with ...
    Medical condition: Sjögren’s syndrome Mixed connective tissue disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:30:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA